Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Myelodysplastic Syndromes
Clinical trial register · United States · industry-sponsored

Myelodysplastic Syndromes Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9183 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 02 Nov 2026, 03:16 UTC
9183
Studies in scope
industry-sponsored, all four open statuses
4981
Recruiting now
open to new participants
2200
Lead sponsors
across recruiting studies
Top states
California 21 Florida 20 New York 16 Texas 16 Maryland 10
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Myelodysplastic Syndromes trials in the USA

32 of 9183 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT07216443Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia
DrugOrca-T
Orca Biosystems, Inc.
Phase 2
80
California, Florida, New Jersey, New York, Oregon, Tennessee
2025-12-09
Recruiting
GlaxoSmithKline
Phase 2
80
Arizona, California, Connecticut, Ohio, Texas
2025-06-05
Recruiting
Takeda
Phase 3
225
California, Connecticut, Florida, Illinois, Kentucky, Louisiana, Maryland, Missouri
2025-05-06
Recruiting
Study of REM-422 in Patients With AML or Higher Risk MDS
NCT06297941Myelodysplastic Syndromes, Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory
Remix Therapeutics
Phase 1
100
California, Florida, Massachusetts, New York, Texas
2024-04-26
Recruiting
GluBio Therapeutics Inc.
Phase 1
48
California, Kansas, New York, Texas
2024-01-11
Active, closed
Bristol-Myers Squibb
Phase 3
402
California, Connecticut, Florida, Hawaii, Illinois, Indiana, Louisiana, Maryland
2023-10-24
Active, closed
Bristol-Myers Squibb
Phase 3
106
California, Connecticut, Florida, Kansas, Kentucky, Michigan, Missouri, New Jersey
2023-10-05
Recruiting
Chordia Therapeutics, Inc.
Phase 1/2
225
Arizona, Florida, Illinois, Minnesota, New York, Texas, Virginia, Washington
2023-04-25
Active, closed
Novartis Pharmaceuticals
Phase 2
33
Oregon, Utah
2023-02-28
Recruiting
Taiho Oncology, Inc.
Phase 1
27
Texas
2022-12-23
Active, closed
Kite, A Gilead Company
Phase 1
24
California, Maryland, Massachusetts, New York, Texas
2022-11-28
Active, closed
Agios Pharmaceuticals, Inc.
Phase 2
87
California, Connecticut, Florida, Illinois, Missouri, New York, North Carolina
2022-11-07
Active, closed
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
NCT05362773Leukemia, Acute Myeloid, Myelodysplastic Syndromes, Classical Hodgkin Lymphoma, Leukemia, B-cell
MacroGenics
Phase 1
130
Colorado, Maryland, Massachusetts, Michigan, Missouri, North Carolina, Texas
2022-07-13
Active, closed
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
NCT05428969Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Relapsed/Refractory AML
Faron Pharmaceuticals Ltd
Phase 1/2
181
California, Connecticut, North Carolina, Texas
2022-06-02
Recruiting
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
NCT04988555Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
Sumitomo Pharma America, Inc.
Phase 1/2
606
California, Colorado, District of Columbia, Florida, Illinois, Maryland, Massachusetts, New Jersey
2022-02-28
Recruiting
Taiho Oncology, Inc.
Phase 1
18
Texas
2021-12-15
Recruiting
A Study of BGB-11417 in Participants With Myeloid Malignancies
NCT04771130Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
BeOne Medicines
Phase 1/2
260
California, Florida, Pennsylvania, Texas, Wisconsin
2021-05-24
Active, closed
A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML
NCT04730258Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, AML
Treadwell Therapeutics, Inc
Phase 1/2
72
California, Kentucky, New York, Ohio, Texas
2021-04-16
Recruiting
Takeda
Phase 2
210
Arkansas, California, Florida, Maryland, Michigan, New Jersey, New York, Pennsylvania
2020-08-19
Recruiting
Syntrix Biosystems, Inc.
Phase 1
151
Florida, Georgia, Maryland, New York
2020-06-30
Recruiting
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
NCT04256317Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm, Chronic Myelomonocytic Leukemia
Taiho Oncology, Inc.
Phase 2/3
316
California, Connecticut, Florida, Georgia, Massachusetts, New Jersey, New York, North Carolina
2020-05-21
Active, closed
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
NCT04013685Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Acute Leukemia
DrugOrca-T
Orca Biosystems, Inc.
Phase 1
155
California, Colorado, Florida, Georgia, Illinois, Kansas, Massachusetts, Michigan
2019-11-21
By invitation
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
NCT04093570Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
Taiho Oncology, Inc.
Phase 2
332
California, Florida, Illinois, Maryland, Michigan, Minnesota, New Jersey, New York
2019-09-30
Active, closed
Precigen, Inc
Phase 1
88
Florida, Minnesota
2019-05-20
Recruiting
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
NCT03802695Acute Myeloid Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia, Acute Lymphoblastic Leukemia
Orca Biosystems, Inc.
Phase 1
300
California, Florida, Georgia, Kansas, New Jersey, New York, Ohio, Texas
2019-04-08
Recruiting
Lixte Biotechnology Holdings, Inc.
Phase 1/2
47
Florida
2019-04
Active, closed
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
NCT02477878Leukemia, Myelodysplastic Syndromes, Lymphoma, Multiple Myeloma
Bellicum Pharmaceuticals
Phase 1
10
Georgia, Kansas, New York, Oregon, Texas
2016-07
Active, closed
Geron Corporation
Phase 2/3
289
Alabama, Arizona, California, Connecticut, Florida, Indiana, Maryland, Missouri
2016-01-12
Active, closed
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
NCT03301168Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes
Bellicum Pharmaceuticals
Phase 1/2
120
California, District of Columbia, Georgia, Massachusetts, New York, Oregon, Texas, Washington
2014-04
Active, closed
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
NCT01744223Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoma, Myelodysplastic Syndromes
Bellicum Pharmaceuticals
Phase 1/2
36
Georgia, New York, Ohio, Oregon, Texas, Washington
2013-03
Rows per page Showing 1–32 of 32
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 3 November 2026. https://priyalifescience.com/clinical-trials-usa/condition/myelodysplastic-syndromes

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,183 studies in total at the last sync on 02 Nov 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 32 of those studies listing the condition Myelodysplastic Syndromes.

How many Myelodysplastic Syndromes trials are recruiting in the US?

15 of the 32 studies on this page are recruiting new participants as of the 02 Nov 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 16 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Myelodysplastic Syndromes), 32 studies
PhaseStudiesRecruitingShare
Phase 111634.4%
Phase 1/28425%
Phase 26318.8%
Phase 34112.5%
Phase 2/3319.4%

Most active sponsors

Lead sponsors with the most studies (Myelodysplastic Syndromes)
Lead sponsorStudiesRecruiting
Taiho Oncology, Inc.43
Bellicum Pharmaceuticals30
Bristol-Myers Squibb30
Orca Biosystems, Inc.32
Takeda22
Agios Pharmaceuticals, Inc.10
BeOne Medicines11
Celgene10
Chordia Therapeutics, Inc.11
Faron Pharmaceuticals Ltd10

Top states

Top states (Myelodysplastic Syndromes), by number of studies with a site there
StateStudies
California21
Florida20
New York16
Texas16
Maryland10
Connecticut9
New Jersey8
Georgia7
Illinois7
Massachusetts7
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.